Exscientia PLC is a drug design and development company. The Company combines precision design with integrated experimentation to invent and develop drugs. It uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. It uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. It has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. It combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The Company's experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its product pipeline consists of GTAEXS617, EXS4318, EXS74539, and EXS73565.

Employees

483

Sector

Biotechnology & Medical Research

Calendar

2025-03-19 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

income-statement-evolution-chart EXSCIENTIA-PLC

More financial data

Market Closed - Nasdaq Other stock markets 04:00:00 2024-11-19 pm EST			5-day change	1st Jan Change
4.840 ^USD	+3.20%		-.--%	-24.49%

Nov. 21	Exscientia plc(NasdaqGS:EXAI) dropped from S&P Global BMI Index	CI
Nov. 20	Recursion Pharmaceuticals, Exscientia Complete Business Combination	MT

Capitalization	500M 636M 604M 561M 894M 53.84B 987M 6.95B 2.58B 22.09B 2.39B 2.33B 95.43B	P/E ratio 2022	-4.55x	P/E ratio 2023	-4.28x
Enterprise value	156M 198M 188M 175M 279M 16.77B 308M 2.16B 804M 6.88B 744M 727M 29.73B	EV / Sales 2022	1.9x	EV / Sales 2023	14.2x
Free-Float	36.87%	Yield 2022 *	-	Yield 2023	-

Exscientia plc(NasdaqGS:EXAI) dropped from S&P Global BMI Index	Nov. 20	CI
Recursion Pharmaceuticals, Exscientia Complete Business Combination	Nov. 20	MT
Recursion Appoints Ben Taylor as Chief Financial Officer	Nov. 20	CI
Recursion Announces Management Changes	Nov. 20	CI
Recursion Pharmaceuticals, Inc. completed the acquisition of Exscientia plc.	Nov. 19	CI
Exscientia plc(NasdaqGS:EXAI) dropped from NASDAQ Composite Index	Nov. 19	CI
Exscientia plc(NasdaqGS:EXAI) dropped from NASDAQ Biotechnology Index	Nov. 19	CI
Recursion Pharmaceuticals, Exscientia Shareholders Approve Proposed Combination	Nov. 13	MT
Exscientia plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 08	CI
Exscientia Expects $15 Million in Milestone Payments From Sanofi	Oct. 16	MT
Exscientia plc Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 07:00 AM	Sep. 04
Exscientia plc Reports Impairment for the Second Quarter Ended June 30, 2024	Aug. 15	CI
Exscientia plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 15	CI

TD Cowen Downgrades Exscientia to Hold	Aug. 09	MT
TD Cowen Initiates Exscientia at Buy	Jul. 09	MT
Barclays Cuts Price Target on Exscientia to $10 From $12, Maintains Overweight Rating	23-10-17	MT
Morgan Stanley Cuts Exscientia Price Target to $7 From $14, Maintains Equal Weight Rating	23-10-10	MT
Berenberg Bank Adjusts Exscientia to $10 From $14, Maintains Buy Rating	23-10-09	MT

Exscientia plc Stock

Equities

EXAI

US30223G1022

Biotechnology & Medical Research

Valuation: Exscientia plc

Chart: Exscientia plc

Latest news: Exscientia plc

Last Transcript: Exscientia plc

Analysts' recommendations: Exscientia plc

Press Releases: Exscientia plc

News in other languages: Exscientia plc

Quotes and Performance

Course Extremes

Managers and Directors: Exscientia plc

ETFs: Exscientia plc

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

Exscientia : Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery Form 6 K	Nov. 20	PU
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery	Nov. 20	AQ
Exscientia : Recursion and Exscientia Shareholders Approve the Proposed Combination Form 6 K	Nov. 13	PU
Exscientia : Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive (Loss)/Income for the three and nine months ended September 30, 2024 and 2023 Form 6 K	Nov. 08	PU
Exscientia : FIRST AMENDMENT TO TRANSACTION AGREEMENT Form 6 K	Nov. 06	PU

Exscientia franchit des étapes importantes pour deux de ses programmes dans le cadre de sa collaboration avec Sanofi	Oct. 16
Exscientia erreicht Meilensteine für zwei Programme im Rahmen der Zusammenarbeit mit Sanofi	Oct. 16
Exscientia présentera de nouvelles données précliniques pour les inhibiteurs de la LSD1 et du MALT1 conçus par l'IA à l'ENA 2024	Oct. 09
Exscientia präsentiert auf der ENA 2024 neue präklinische Daten für KI-gestützte LSD1- und MALT1-Inhibitoren	Oct. 09
Exscientia wird auf der 22nd Annual Global Healthcare Conference Präsentation durchführen	Aug. 28

1 day	+3.20%
1 month	-3.39%
3 months	-2.42%
6 months	-15.97%
Current year	-24.49%

Director	Title	Age	Since
Eileen Jennings-Brown CTO	Chief Tech/Sci/R&D Officer	-	2022-04-30
Marie-Louise Fjaellskog CTO	Chief Tech/Sci/R&D Officer	59	2024-06-05
John Overington CTO	Chief Tech/Sci/R&D Officer	-	2024-04-30

Manager	Title	Age	Since
Mario Polywka BRD	Director/Board Member	61	2017-09-27
Robert Ghenchev BRD	Director/Board Member	41	2020-04-30
Elizabeth Crain CHM	Chairman	59	2024-02-11

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
EXSCIENTIA PLC	+3.20%	-.--%	-21.68%	-75.33%	633M
LONZA GROUP AG	-0.30%	+1.54%	+58.30%	-25.18%	43.21B
IQVIA HOLDINGS INC.	+1.29%	+0.86%	-6.06%	-22.36%	36.88B
CELLTRION, INC.	-2.09%	+2.92%	+12.55%	-7.78%	26.71B
ICON PUBLIC LIMITED COMPANY	+0.71%	+0.78%	-19.55%	-21.37%	17.71B
UNITED THERAPEUTICS CORPORATION	+1.52%	-0.99%	+56.04%	+101.30%	16.71B
MODERNA, INC.	-2.23%	-4.06%	-47.88%	-86.43%	16.02B
BIO-TECHNE CORPORATION	+1.12%	+0.68%	+16.22%	-33.45%	12.06B
MEDPACE HOLDINGS, INC.	+2.08%	+2.17%	+23.89%	+68.00%	10.74B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.03%	-0.12%	-0.63%	-44.22%	10.19B
Average	+0.90%	+0.06%	+7.12%	-14.68%	19.09B
Weighted average by Cap.	+0.41%	+0.26%	+15.12%	-12.37%

	2022	2023
Net sales	27.22M 34.61M 32.87M 30.57M 48.71M 2.93B 53.78M 378M 141M 1.2B 130M 127M 5.2B	20.08M 25.53M 24.24M 22.55M 35.93M 2.16B 39.66M 279M 104M 887M 95.88M 93.78M 3.83B
Net income	-119M -151M -143M -133M -212M -12.79B -235M -1.65B -613M -5.25B -567M -555M -22.67B	-146M -186M -176M -164M -261M -15.72B -288M -2.03B -754M -6.45B -697M -682M -27.87B
Net Debt	-492M -625M -594M -552M -880M -52.99B -972M -6.84B -2.54B -21.74B -2.35B -2.3B -93.92B	-344M -438M -416M -386M -616M -37.07B -680M -4.78B -1.78B -15.21B -1.64B -1.61B -65.7B